23:21

Key Insights in MPN & MDS: from the US Focus on MPN & MDS 2017

HMP Education

19:01

Myelodysplastic syndromes: Genomic landscape

HMP Education

16:25

Advances in understanding of MDS microenvironment

HMP Education

19:50

Role of immune system in MDS pathogenesis

HMP Education

19:10

New mouse models of MPN

HMP Education

22:10

Mechanisms of bone marrow fibrosis in myelofibrosis

HMP Education

27:27

Biology and therapy of advanced mastocytosis

HMP Education

21:27

Topical challenges in the management of ET

HMP Education

12:34

Is there still a role for splenectomy and splenic radiation in management of MPN?

HMP Education

29:27

My view on current and future use of JAK inhibitors for ET, PV, and MF

HMP Education

19:20

CHIP & ICUS: What do we know and what do we need to do?

HMP Education

33:47

My approach to MDS management

HMP Education

24:17

Iron chelation therapy for MDS

HMP Education

22:15

Optimal use of lenalidomide as therapy for MDS

HMP Education

22:41

New opportunities in experimental therapeutics in MDS

HMP Education

21:11

MF marrow morphology: Key takeaways from WHO 2016 diagnostic update

HMP Education

30:30

What is new in thrombosis in MPN

HMP Education

21:33

Therapeutic insights in clonal evolution of MPN to accelerated or blastic phase

HMP Education

20:03

My approach to MF management

HMP Education

29:07

Experimental therapeutics in MPN: Where is the field going?

HMP Education